University Cancer Research Fund
The University Cancer Research Fund (UCRF) is a nation-leading investment to stimulate cancer research and reduce North Carolina’s leading cause of death. The Fund builds upon the exceptional research base at UNC Lineberger Comprehensive Cancer Center, the state’s only public, NCI-designated comprehensive cancer center.
UCRF’s Goal
To create a nation-leading cancer research effort and to reduce North Carolina’s cancer burden. UCRF is accomplishing these goals through:
- Discovery to better understand the causes and course of cancer.
- Innovation to create new and better ways to prevent, diagnose and treat cancer.
- Delivery of improved cancer care, screening and prevention across the state.
Latest News
-
Study reveals most effective anti-vaping messages for teens
Seth Noar, PhD, Marcella Boynton, PhD, and colleagues report that effective anti-vaping advertisements geared to teens have the greatest impact when they emphasize adverse consequences and harms.
-
Nanotechnology offers lower cost, high accuracy approach to diagnosing leukemias in low resource countries
A newer, less expensive nanotechnology may make it possible to more accurately diagnose children with acute leukemia in lower income countries, according to findings by Thomas Alexander, MD, MPH, and colleagues.
-
Scientists uncover a new approach for treating aggressive cancer
Greg Wang, PhD, and colleagues have uncovered a new role of a chromatin-modulatory enzyme, termed EZH2, during cancer development.
-
Weekly electronic reporting of symptoms improves care for patients with advanced cancer
People with advanced cancers who reported their symptoms weekly using a digital tool received more timely, and potentially life-saving treatment, compared to those who were evaluated less frequently via regular in-person clinical visits, according to findings from a national study led by Ethan Basch, MD, MSc.
-
Experimental drug that boosts immunotherapy shows promise in bladder cancer study
William Kim, MD, and colleagues have published findings that adding the experimental drug entinostat to an immunotherapy-like treatment substantially boosted cancer remission in laboratory models.